Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Capital Expenditures (2016 - 2025)

Capricor Therapeutics (CAPR) has 14 years of Capital Expenditures data on record, last reported at $55843.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 510.64% year-over-year to $55843.0; the TTM value through Sep 2025 reached $1.7 million, up 39.76%, while the annual FY2024 figure was $1.2 million, 11.04% down from the prior year.
  • Capital Expenditures reached $55843.0 in Q3 2025 per CAPR's latest filing, down from $287738.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $896007.0 in Q1 2025 and bottomed at $9145.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $363928.8, with a median of $347690.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: skyrocketed 1437.75% in 2022, then tumbled 96.61% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $368671.0 in 2021, then skyrocketed by 88.26% to $694044.0 in 2022, then fell by 19.51% to $558604.0 in 2023, then fell by 12.5% to $488798.0 in 2024, then tumbled by 88.58% to $55843.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $55843.0 in Q3 2025, $287738.0 in Q2 2025, and $896007.0 in Q1 2025.